idc btig estim compani document
million except per share amount
unwav focu new product innov capit
attract end market leverag scale buy pt
reiter buy rais pt
result handili beat consensu expect top
bottom line includ organ revenu growth full year guidanc
also rais top bottom line includ organ revenu growth
outlook year vs previous cant think one thing
nitpick quarter repres quarter row
achiev double-digit biopharma segment growth well continu strength
china growth y/i highlight quarter includ high singl digit
growth across europ asia-pacif diagnost healthcar segment round
rest end market north america academ govern
segment grew mid-singl digit industri appli flat y/i
high singl digit growth
look last three year tmo industri averag growth get
harder harder attribut strong consist perform predominantli
attract end market condit alon believ compani better
posit ever take market share also grow overal
market faster rate one key growth strategi may
underappreci view new product innov budget
billion help highli disciplin term invest priorit
similar high hurdl establish given depth scale
compani expertis uniqu posit directli engag gain
insight earli custom along process join day
custom china despit grow uncertainti macro environ
remain well-entrench valuabl vendor provid product expertis
critic achiev mani govern prioriti part
protect etc given defens strateg posit market
believ tmo outlook remain bright well next year
updat estim reflect updat guidanc
estim adjust reflect result well slightli worsen fx
environ revenu estim slightli lower ep
estim slightli higher long histori trade discount
peer group think given compani track record growth trajectori
ahead premium forward price-to-earnings multipl warrant
model updat revenu ep estim y/i
vs prior y/i vs prior
revenu ep estim y/i vs prior
assum fx headwind vs tailwind prior
valuat pt base price-to-earnings
largest compani life scienc tool industri better posit ever view
capit fastest grow market segment well take share competitor leverag
 budget economi scale strateg invest made last sever year high growth area
continu priorit oper effici initi better ever organ revenu growth
outlook capit deploy potenti ahead believ minimum line price-to-earnings multipl
warrant vs peer group life scienc tool compani
financi result midpoint compani guidanc
perform midpoint compani three-year
includ potenti futur acquisit gener in-lin
guidanc includ addit leverag full capit deploy
thermo fisher scientif
largest compani life scienc
tool industri revenu
reagent chemic suppli
servic research biopharma
industri diagnost clinic
appli market thermo also
provid scientif product
channel busi
thermo headquart
better-than-expect nt lt financi perform
faster-than-expect capit deploy
worse-than-expect nt lt financi perform
signific and/or prolong deterior demand across tmo end
exhibit varianc million except per share data
exhibit end market observ geographi growth constant currenc
ht
china
china
hsd
msd fy
hsd
hsd fy
lt mt
fy
china
msd
hsd fy
china
china
china
actualstreet estimate btig chang profit gross margin incom oper margin rate incom chang
across
across
across
saw
increas
flow
fund
fy
across
fy
fy
strength
fy
exhibit end market observ end market growth constant currenc
across
across
demand
bio-
pharma
strength
condit
america
strength
also
demand
analysi
across
strength
north
europ
acquisit
complet
bioprocess off-set
divestitur creat
y/i headwind
headwind
revenu major
expect
divestitur
anatom patholog
incl bp headwind
tariff reflect full
tariff
current place
increas outlook
benefit time
anatom
full year headwind
increment
acquisit
headwind fy impact
contribut
acquisit brammer
expect close
due fx brammer
headwind fx
headwind fx
full year fx impact
headwind
assum debt
assum debt
repay
repay
headwind
incl dilut
sale anatom
incl fx headwind
incl accret
brammer
incl fx headwind
updat
incl dilut
sale anatom
accret advanc
incl headwind tariff
unchang
benefit non-
oper fx
increas
midpoint consist
stronger
better fx
time
incl fx headwind
share
benefit recent
increas
midpoint consist
strong
expens debt
increas
share buyback earli
incl fx headwind
updat
expect off-set increment
invest strong
expans invest
repo
complet earli
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig research
btig cover compani mention report
appendix analyst certif import disclosur
